secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K/A
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010114
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4
--------------------------------------------------------------------------------

- Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.
- Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.
- Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).
- Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.
- Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/0001193125-26-010114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/bdsx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer